Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial (FORE-PAIN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06051227 |
Recruitment Status :
Recruiting
First Posted : September 22, 2023
Last Update Posted : January 17, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Fentanyl and esketamine are both standard of care for treatment of acute severe traumatic pain in the prehospital setting in the Netherlands. However, it is not known whether they are equally effective and safe. It is also not known whether intranasal (IN) administration of fentanyl or esketamine is equally effective and safe as intravenous (IV) administration.
The FORE-PAIN trial is a double-blind multi-arm randomized non-inferiority trial comparing Fentanyl IN, esketamine IV and esketamine IN (intervention arms) to fentanyl IV (comparator arm) for prehospital management of traumatic pain. The investigators hypothesize that all intervention arms provide analgesia that is non-inferior to the comparator arm, and that all study arms are equally safe.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Pain Due to Trauma Analgesia Fentanyl Esketamine Emergency Medical Services | Drug: Fentanyl Citrate Drug: Esketamine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 608 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial |
Actual Study Start Date : | January 11, 2024 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Fentanyl IV
Opioid analgesic Form: fentanyl solution for injection/infusion Administration: intravenous Initial dose: 1 ug/kg Second dose (if required): 0.6ug/kg
|
Drug: Fentanyl Citrate
Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal |
Experimental: Fentanyl IN
Opioid analgesic Form: fentanyl solution for injection/infusion Administration: intranasal using nasal atomizer Initial dose: 1.25 ug/kg to a maximum of 100ug Second dose (if required): 1ug/kg to a maximum total dose of 2ug/kg
|
Drug: Fentanyl Citrate
Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal |
Experimental: Esketamine IV
Anesthetic, in lower doses the analgesic effect is dominant Form: esketamine solution for injection/infusion Administration: intravenous Initial dose: 0.2mg/kg Second dose (if required): 0.12mg/kg
|
Drug: Esketamine
Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal |
Experimental: Esketamine IN
Anesthetic, in lower doses the analgesic effect is dominant Form: esketamine solution for injection/infusion Administration: intranasal using a nasal atomizer Initial dose: 0.625mg/kg to a maximum of 50mg Second dose (if required): 0.5mg/kg to a maximum total dose of 1mg/kg
|
Drug: Esketamine
Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal |
- Change in pain score as measured with Numeric Rating Scale (NRS) [ Time Frame: 10 minutes after first drug administration ]NRS is an 11 point Likert scale ranging from 0 to 10, where 0 means 'no pain' and 10 means 'worst pain imaginable'
- Change in pain score as measured with NRS [ Time Frame: 20 minutes after first drug administration; time of arrival at the hospital (expected within 30 minutes after first drug administration) ]NRS is an 11 point Likert scale ranging from 0 to 10, where 0 means 'no pain' and 10 means 'worst pain imaginable'
- Relative change in pain score as measured with NRS [ Time Frame: 10 and 20 minutes after first drug administration; time of arrival at the hospital (expected within 30 minutes after first drug administration) ]NRS is an 11 point Likert scale ranging from 0 to 10, where 0 means 'no pain' and 10 means 'worst pain imaginable'
- Number of subjects requiring a second dose of study medication [ Time Frame: 10 and 20 minutes after first drug administration ]If the patient requires additional analgesia, study medication can be repeated once
- Patient satisfaction with pre-hospital analgesia [ Time Frame: Time of arrival at the hospital (expected within 30 minutes after first drug administration) ]Patient satisfaction is measured using an 11 point Likert scale ranging from 0 to 10, where 0 means 'extremely unsatisfactory' and 10 means 'extremely satisfactory'
- Number of patients experiencing adverse events [ Time Frame: Up to time of arrival at the hospital (expected within 30 minutes after first drug administration) ]Including side effects
- Number of patients requiring unblinding [ Time Frame: Up to time of arrival at the hospital (expected within 30 minutes after first drug administration) ]E.g. because of treatment failure or side effects
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age ≥ 18 years
- pain has been caused by a trauma (any trauma mechanism) that occurred on the same day
- Emergency Medical Services personnel determines that administration of a strong opioid or esketamine for analgesia is required
- patient will be transported to a hospital
Exclusion Criteria:
- (estimated) weight <40 or >100 kg
- subject does not understand Dutch or English
- inability to report pain score
- inability to give IN or IV medication
- known severe cardiovascular disease
- pre-eclampsia
- Glasgow Coma Scale score < 11
- subject is known to have previously declined participation in medical research
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06051227
Contact: Robert P Weenink, PhD | +31 205669111 | forepain@amsterdamumc.nl |
Netherlands | |
Ambulance Amsterdam | Recruiting |
Amsterdam, Netherlands | |
Contact: Midas de Grunt, MD forepain@amsterdamumc.nl |
Principal Investigator: | Markus W Hollmann, Prof. dr. dr. | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Responsible Party: | Robert Weenink, Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
ClinicalTrials.gov Identifier: | NCT06051227 |
Other Study ID Numbers: |
FP-2023 2022-500176-63-00 ( Other Identifier: EU Clinical Trials Information System ) U1111-1287-7486 ( Other Identifier: ICTRP ) 2022-000039-22 ( EudraCT Number ) |
First Posted: | September 22, 2023 Key Record Dates |
Last Update Posted: | January 17, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Metadata and the final data will be published. Conditions for reuse apply. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | Metadata are published before locking of the database. The final data are published at the time of the journal article's publication. |
Access Criteria: | Conditions for reuse of data are described in the patient information folder. Access to the data can be granted by the Principal Investigator based on these criteria. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Analgesics Ketanest Administration, intranasal Administration, intravenous |
Pain management Drug-Related Side Effects and Adverse Reactions Anesthetics |
Emergencies Acute Pain Disease Attributes Pathologic Processes Pain Neurologic Manifestations Fentanyl Esketamine Analgesics, Opioid Narcotics Central Nervous System Depressants |
Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Adjuvants, Anesthesia Anesthetics, Intravenous Anesthetics, General Anesthetics Antidepressive Agents Psychotropic Drugs |